Market Overview:
The Global Next Generation Gynecological Cancer Diagnostic Market size is expected to grow from USD 2.41 billion in 2022 to USD 5.43 billion by 2030, at a CAGR of 10.70% during the forecast period (2023-2030).
Gynecologic cancer refers to cancer that originates in a woman's reproductive organs. It is named after the specific body part where it initially appears and can occur anywhere in the pelvic region, which is the area beneath the stomach and between the hip bones. Various types of gynecologic cancer exist, including cervical, ovarian, uterine, vaginal, and vulvar cancers. Among these, ovarian cancer is the most common. The advancement of technology has led to the emergence of innovative diagnostic techniques for gynecologic cancer, such as quantitative polymerase chain reaction (qPCR) and multiplexing, next-generation sequencing, lab-on-a-chip (LOAC), and reverse transcription-polymerase chain reaction (RT-PCR), and microarray. These technological advancements in sequencing have greatly supported researchers and clinics in gaining knowledge and discovering biomarkers for guidance.
Top Key Players for Next Generation Gynecological Cancer Diagnostic Market:
- Agilent Technologies (US)
- ARUP Laboratories (US)
- BGI Genomics (China)
- CENTOGENE N.V. (Germany)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Fulgent Genetics (US)
- Illumina Inc. (US)
- Invitae Corporation (US)
- Konica Minolta Inc. (Japan)
- Laboratory Corporation of America Holdings (US)
- Myriad Genetics (US)
- OPKO Health Inc. (US)
- QIAGEN N.V. (Germany)
- Quest Diagnostics Incorporated (US)
- Thermo Fisher Scientific Inc. (US), and Other Major Players
Market Dynamics and Factors:
The growing prevalence of cervical and ovarian cancer is a significant driver of the next-generation gynecological cancer diagnostic market. Cervical and ovarian cancers are among the most common types of gynecologic cancers and pose a considerable health burden worldwide.
Cervical cancer, in particular, has been a major public health concern, causing a significant number of deaths among women. The human papillomavirus (HPV) infection is a primary risk factor for cervical cancer, and its prevalence has contributed to the rising incidence of this disease. Efforts to prevent cervical cancer, such as HPV vaccination programs and screening initiatives, have increased awareness and early detection rates. However, the growing prevalence of cervical cancer necessitates the development of advanced diagnostic technologies to improve detection accuracy and guide treatment decisions.
Government initiatives aimed at reducing the burden of cancer present an opportunity in the field of gynecological cancer diagnostics. Recognizing the significant impact of cancer on public health, governments worldwide have implemented various initiatives to address the prevention, early detection, and treatment of cancer, including gynecologic cancers. These government initiatives often involve public awareness campaigns, education programs, and policy interventions. For instance, governments may launch vaccination programs against HPV, which is a leading cause of cervical cancer. By promoting HPV vaccinations, governments aim to reduce the incidence of cervical cancer and its associated healthcare costs.
Key Industry Development:
In June 2023, Agilent InfinityLab GPC/SEC acquired Polymer Standard Service Ltd. (PSS). This integration encompassed a dedicated GPC/SEC Column Thermostat, a Multi-Angle Light Scattering Detector, the GPC/SEC-Ready Kit, and the powerful WinGPC Software, augmenting the existing InfinityLab GPC/SEC Solutions for advanced material characterization
In Sept 2022, -Thermo Fisher Scientific Inc., the world leader in serving science, unveiled the Thermo Scientific™ DynaSpin™ Single-Use Centrifuge system at the BioProcess International annual conference in Boston, MA. The system is specifically designed to provide an optimal single-use solution for large-scale cell culture harvesting. The DynaSpin system improves and streamlines harvesting for cell culture separation in single-use bioprocesses by reducing the number of depth filtration cartridges required to complete the harvest process
Next Generation Gynecological Cancer Diagnostic Market Report Highlight:
- By Technology, the Next Generation Sequencing segment holds a larger market share, NGS has emerged as a valuable tool for obtaining detailed insights into the molecular characteristics of individual tumors, surpassing the capabilities of traditional approaches
- By Function, The companion diagnostics Segment is expected to register the highest growth during the projected period. Companion diagnostics have gained prominence due to their ability to match patients with the most suitable treatment options based on their individual genetic makeup or specific biomarkers.
- By Application, the biomarker segment is estimated to develop the fastest, because Biomarkers play a crucial role in the diagnosis, prognosis, and personalized treatment of gynecological cancers.
- The North American region is expected to have the highest share of the Next Generation Gynecological Cancer Diagnostic market over the projected period. The region boasts a well-established healthcare infrastructure and a high level of technological advancements.
Central to our report are the company profiles and competitive analysis, providing insights into market players' overview, market roles, and operating business segments. We evaluate their financial performance, production volume, sales volume, and sales margin while highlighting recent market developments. Our market research offers invaluable intelligence and strategic insights to drive informed decision-making. By capitalizing on emerging opportunities and understanding the competitive landscape, our report empowers businesses to thrive in the Global Next Generation Gynecological Cancer Diagnostic Market.
Next Generation Gynecological Cancer Diagnostic Market Segmentation:
By Technology
- qPCR & Multiplexing
- Next-Generation Sequencing
- LOAC & RT-PCR
- Other
By Function
- Companion Diagnostics
- Therapeutic & Monitoring
- Prognostic
- Cancer Screening
- Risk Analysis
By Application
- Biomarker Development
- CTC Analysis
- Proteomic Analysis
- Epigenetic Analysis
- Others
